Aurobindo Pharma Ltd Q2FY17
Consolidated Results Q2FY17: (Rs. in crore)
|EBITDA Margin (%)||24.6||146|
|Net Profit (adjusted)||606||33.5|
Aurobindo Pharma Ltd’s Q2FY17 consolidated numbers came in mixed from our estimates. Revenue was 2.1% down from our estimates of Rs 3856.7 cr. Company’s EBITDA was 0.9% below the estimated figure of Rs 937 cr. Company’s net profit however, stood 0.6% above the estimates of Rs 602 cr.
Company’s net revenue stood at Rs 3775.5 cr which grew 12.2% during the corresponding quarter of previous year. Company's formulation sales to USA grew 17.8% yoy to Rs 1735.1 cr. Moreover, revenues from Betalactum API (Active Pharmaceutical Ingredients) grew 19.6% yoy to Rs 511.3 cr.
EBITDA surged by 19.3% yoy to Rs 929 cr and EBITDA margins expanded 146 bps yoy to 24.6%.
Company's net profit rose 33.5% yoy to Rs 605.65 cr. This was driven by 27% yoy drop in finance costs.
Aurobindo Pharma Ltd ended at Rs. 792, up by 20.1 points or 2.6% from its previous closing of Rs. 771.9 on the BSE.
The scrip opened at Rs. 792 and touched a high and low of Rs. 792 and Rs. 792 respectively. A total of 8453(NSE+BSE) shares were traded on the counter. The stock traded above its 50 DMA.
BSE 677.85 [8.05] ([1.17]%)
NSE 678.20 [7.85] ([1.14]%)
***Note: This is a NSE Chart